BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 35383193)

  • 1. Author Correction: The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.
    Rosen EY; Won HH; Zheng Y; Cocco E; Selcuklu D; Gong Y; Friedman ND; de Bruijn I; Sumer O; Bielski CM; Savin C; Bourque C; Falcon C; Clarke N; Jing X; Meng F; Zimel C; Shifman S; Kittane S; Wu F; Ladanyi M; Ebata K; Kherani J; Brandhuber BJ; Fagin J; Sherman EJ; Rekhtman N; Berger MF; Scaltriti M; Hyman DM; Taylor BS; Drilon A
    Nat Commun; 2022 Apr; 13(1):1936. PubMed ID: 35383193
    [No Abstract]   [Full Text] [Related]  

  • 2. The evolution of RET inhibitor resistance in RET-driven lung and thyroid cancers.
    Rosen EY; Won HH; Zheng Y; Cocco E; Selcuklu D; Gong Y; Friedman ND; de Bruijn I; Sumer O; Bielski CM; Savin C; Bourque C; Falcon C; Clarke N; Jing X; Meng F; Zimel C; Shifman S; Kittane S; Wu F; Ladanyi M; Ebata K; Kherani J; Brandhuber BJ; Fagin J; Sherman EJ; Rekhtman N; Berger MF; Scaltriti M; Hyman DM; Taylor BS; Drilon A
    Nat Commun; 2022 Mar; 13(1):1450. PubMed ID: 35304457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of RET protein-tyrosine kinase inhibitors in the treatment RET-driven thyroid and lung cancers.
    Roskoski R; Sadeghi-Nejad A
    Pharmacol Res; 2018 Feb; 128():1-17. PubMed ID: 29284153
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Targeted Therapy with BLU-667 for
    Subbiah V; Gainor JF; Rahal R; Brubaker JD; Kim JL; Maynard M; Hu W; Cao Q; Sheets MP; Wilson D; Wilson KJ; DiPietro L; Fleming P; Palmer M; Hu MI; Wirth L; Brose MS; Ou SI; Taylor M; Garralda E; Miller S; Wolf B; Lengauer C; Guzi T; Evans EK
    Cancer Discov; 2018 Jul; 8(7):836-849. PubMed ID: 29657135
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selpercatinib for lung and thyroid cancers with RET gene mutations or fusions.
    Zheng H; Chen ZS; Li J
    Drugs Today (Barc); 2021 Oct; 57(10):621-629. PubMed ID: 34713870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Decade in review: a new era for RET-rearranged lung cancers.
    Choudhury NJ; Drilon A
    Transl Lung Cancer Res; 2020 Dec; 9(6):2571-2580. PubMed ID: 33489819
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Precision oncology with selective RET inhibitor selpercatinib in
    Gouda MA; Subbiah V
    Ther Adv Med Oncol; 2023; 15():17588359231177015. PubMed ID: 37360768
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The budget impact of adding pralsetinib to a US health plan formulary for treatment of non-small cell lung cancer and thyroid cancer with
    Duff S; Bargiacchi F; Norregaard C; Brener M; Sullivan E
    J Manag Care Spec Pharm; 2022 Feb; 28(2):218-231. PubMed ID: 34726500
    [No Abstract]   [Full Text] [Related]  

  • 9. Targeting RET alterations in cancer: Recent progress and future directions.
    Shabbir A; Kojadinovic A; Shafiq T; Mundi PS
    Crit Rev Oncol Hematol; 2023 Jan; 181():103882. PubMed ID: 36481304
    [TBL] [Abstract][Full Text] [Related]  

  • 10. RET kinase inhibitors for
    Vodopivec DM; Hu MI
    Ther Adv Med Oncol; 2022; 14():17588359221101691. PubMed ID: 35756966
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Precious Gene: The Application of RET-Altered Inhibitors.
    Gou Q; Gan X; Li L; Gou Q; Zhang T
    Molecules; 2022 Dec; 27(24):. PubMed ID: 36557971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1/2, open-label, basket trial.
    Subbiah V; Wolf J; Konda B; Kang H; Spira A; Weiss J; Takeda M; Ohe Y; Khan S; Ohashi K; Soldatenkova V; Szymczak S; Sullivan L; Wright J; Drilon A
    Lancet Oncol; 2022 Oct; 23(10):1261-1273. PubMed ID: 36108661
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overcoming MET-Dependent Resistance to Selective RET Inhibition in Patients with RET Fusion-Positive Lung Cancer by Combining Selpercatinib with Crizotinib.
    Rosen EY; Johnson ML; Clifford SE; Somwar R; Kherani JF; Son J; Bertram AA; Davare MA; Gladstone E; Ivanova EV; Henry DN; Kelley EM; Lin M; Milan MSD; Nair BC; Olek EA; Scanlon JE; Vojnic M; Ebata K; Hechtman JF; Li BT; Sholl LM; Taylor BS; Ladanyi M; Jänne PA; Rothenberg SM; Drilon A; Oxnard GR
    Clin Cancer Res; 2021 Jan; 27(1):34-42. PubMed ID: 33082208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ponatinib (AP24534) is a novel potent inhibitor of oncogenic RET mutants associated with thyroid cancer.
    De Falco V; Buonocore P; Muthu M; Torregrossa L; Basolo F; Billaud M; Gozgit JM; Carlomagno F; Santoro M
    J Clin Endocrinol Metab; 2013 May; 98(5):E811-9. PubMed ID: 23526464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pralsetinib: chemical and therapeutic development with FDA authorization for the management of RET fusion-positive non-small-cell lung cancers.
    Ali F; Neha K; Chauhan G
    Arch Pharm Res; 2022 May; 45(5):309-327. PubMed ID: 35598228
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges in diagnosis and biomarker testing for RET-altered lung and thyroid cancer care: an international mixed-method study.
    Lazure P; Sireci A; Subbiah V; Murray S; Grohé C; Sherman SI; Kelly E; Bubach P; Péloquin S
    BMC Med Educ; 2023 Jun; 23(1):410. PubMed ID: 37277734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Precision therapy for RET-altered cancers with RET inhibitors.
    Thein KZ; Velcheti V; Mooers BHM; Wu J; Subbiah V
    Trends Cancer; 2021 Dec; 7(12):1074-1088. PubMed ID: 34391699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [RET Gene Alterations in Thyroid Cancer-Towards Treatment with Selective RET Inhibitors].
    Mitsutake N; Nakamura K; Suzuki S
    Gan To Kagaku Ryoho; 2023 May; 50(5):611-614. PubMed ID: 37218322
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of Cell-Free DNA from 32,989 Advanced Cancers Reveals Novel Co-occurring Activating
    Rich TA; Reckamp KL; Chae YK; Doebele RC; Iams WT; Oh M; Raymond VM; Lanman RB; Riess JW; Stinchcombe TE; Subbiah V; Trevarthen DR; Fairclough S; Yen J; Gautschi O
    Clin Cancer Res; 2019 Oct; 25(19):5832-5842. PubMed ID: 31300450
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characterization of LDD-2633 as a Novel RET Kinase Inhibitor with Anti-Tumor Effects in Thyroid Cancer.
    Lee HJ; Jeong P; Moon Y; Choi J; Heo JD; Kim YC; Han SY
    Pharmaceuticals (Basel); 2021 Jan; 14(1):. PubMed ID: 33419162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.